Pneumococcal Polysaccharide Conjugate Vaccine
Not recommended ImmunologyRestrictedFirst-line line
For immunisation of all Australian infants and children from the age of eight weeks to two years of age against disease caused by Streptococcus pneumoniae serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F (including invasive disease, pneumonia, and acute otitis media).
1
Submissions
2009–09
On the record
—
ICER range
Cost-min
Cost basis
Decisions on record
- Meeting Nov 2018 Not recommended Prevention of pneumococcal disease
- Meeting Jul 2010 Recommended Vaccine for Pneumococcal disease.
- Meeting Jul 2009 Recommended Vaccination against childhood infections due to Streptococcus pneumoniae . no PSD
Access path
- 2009Recommended · restricted
vs 7 valent pneumococcal conjugate vaccine (Prevenar®)
- PBS listing · Restricted
RecommendedDeferredNot recommended
Cost-effectiveness
Cost minimisation analysis performed; no ICER calculated
Cost-effectiveness accepted
Decision context
PopulationAll Australian infants and children from the age of eight weeks to two years of age
Submission history
| Decided | Outcome | Comparator | ICER | Evidence |
|---|---|---|---|---|
| 2009 | Recommended · restricted | 7 valent pneumococcal conjugate vaccine (Prevenar®) | — | RCT · ELISA with 22F pre-adsorption for assessment of immunogenicity, Opsonophagocytic assay (OPA), Protein D measured using ELISA |
Similar precedents
Pneumococcal Polysaccharide Conjugate Vaccine, 13-Valent82%Pneumococcal Conjugate Vaccine, 15-Valent81%Pneumococcal Conjugate Vaccine, 20-Valent80%Pneumococcal Polysaccharide Conjugate 13-Valent79%Pneumococcal Polysaccharide Conjugate Vaccine, 20-Valent79%Pneumococcal Conjugate Vaccine 13-Valent (13vpcv) And Pneumococcal Polysaccharide Vaccine 23-Valent (23vppv)77%21-Valent Pneumococcal Conjugate Vaccine74%Pneumococcal Conjugate Vaccine, 13-Valent73%
Regulatory · TGA
Label narrower than PBS population — PBAC restricts to age ≥8 weeks versus TGA label starting at 6 weeks; otherwise populations match.